ACI: The FDA’s Office of Generic Drugs to Speak at ACI’s Summit on Generic Drugs

NEW YORK - May 8, 2014 - PRLog -- American Conference Institute (“ACI”) is pleased to announce that Keith Flanagan, Transition Lead for Policy at the United States Food and Drug Administration’s Office of Generic Drugs will give a keynote address at ACI’s Second Annual Legal and Regulatory Summit on Generic Drugs which will take place in New York City on July 23-25, 2014.  This unique event will feature a distinguished faculty of over thirty leading legal and regulatory experts from the generic drug industry who will address the generic drug industry’s present and future challenges.

As Lisa J. Piccolo, Senior Industry Manager, Life Sciences and Health Care with ACI stated, “ACI is proud and honored to bring the generic drug industry to opportunity to hear from Keith Flanagan and the Office of Generic Drugs on important matters affecting and altering the industry’s legal and regulatory landscape.”

The presence of the Office of Generic Drugs together with the Generic Pharmaceutical Association (“GPhA”) and the “who’s who” of the generic drug industry’s top legal and regulatory professionals make this event an essential gathering for legal practitioners and regulatory representatives working in the generic drug industry.  In addition to OGD and GPhA, the distinguished faculty also includes leading representatives from generic drug makers such as Mylan, Teva Pharmaceutical Industries, Perrigo, Lupin, Impax, Akorn, Amneal, Caraco, and Harvest Moon Pharmaceuticals.

More information about this event, including a full agenda, faculty list, and brochure can be accessed at www.AmericanConference.com/GenericDrugs.